Abstract
The excessive activation of neutrophils generates reactive oxygen species (ROS) and the secretion of primary granular enzymes, such as myeloperoxidase (MPO), which is implicated in numerous inflammatory diseases. The aim of this study was to evaluate chalcones as inhibitors of the chlorinating activity of MPO using in vitro and ex vivo assays. In addition to cytotoxic properties, the inhibition of respiratory burst, the scavenger capacity, and the oxidation potential were measured. 4’-Aminochalcone (1), 4’-amino-4- fluorochalcone (2), and 4’-amino-4-methylchalcone (3) exhibited potent inhibition of the chlorinating activity of MPO, as evaluated in a neutrophil system and a free cell system, to the following degree: (1) IC50 = 0.265 ± 0.036 μmol L-1; (2) IC50 = 0.250 ± 0.081 μmol L-1; and (3) IC50 = 0.250 ± 0.012 μmol L-1. These values were similar to those for 5-fluorotryptamine (IC50 = 0.192 ± 0.012 μmol L-1), a compound considered to be a potent MPO inhibitor. These aminochalcones were not toxic to neutrophils at concentrations below 100 μmol L- 1, as determined by the trypan blue exclusion assay. Compounds 1–3 presented a high oxidation potential (Epa1 ≈ 0.80 V), low scavenger capacity against DPPH• and HOCl, and low inhibition of respiratory burst. These data indicated that aminochalcones are potent inhibitors of MPO chlorinating activity, a new property for chalcone derivatives, given that they are neither antioxidant agents nor inhibitors of respiratory burst. In conclusion, the selected aminochalcones have potential as pharmacological agents for inflammatory diseases.
Keywords: Anti-inflammatory, antioxidant, chalcones, hypochlorous acid, myeloperoxidase inhibition, neutrophils, aminochalcones, reactive oxygen species, redox potential, scavenger capacity
Current Medicinal Chemistry
Title:4’-Aminochalcones As Novel Inhibitors of the Chlorinating Activity of Myeloperoxidase
Volume: 19 Issue: 31
Author(s): M.L. Zeraik, V.F. Ximenes, L.O. Regasini, L.A. Dutra, D.H.S. Silva, L.M. Fonseca, D. Coelho, S.A.S. Machado and V.S. Bolzani
Affiliation:
Keywords: Anti-inflammatory, antioxidant, chalcones, hypochlorous acid, myeloperoxidase inhibition, neutrophils, aminochalcones, reactive oxygen species, redox potential, scavenger capacity
Abstract: The excessive activation of neutrophils generates reactive oxygen species (ROS) and the secretion of primary granular enzymes, such as myeloperoxidase (MPO), which is implicated in numerous inflammatory diseases. The aim of this study was to evaluate chalcones as inhibitors of the chlorinating activity of MPO using in vitro and ex vivo assays. In addition to cytotoxic properties, the inhibition of respiratory burst, the scavenger capacity, and the oxidation potential were measured. 4’-Aminochalcone (1), 4’-amino-4- fluorochalcone (2), and 4’-amino-4-methylchalcone (3) exhibited potent inhibition of the chlorinating activity of MPO, as evaluated in a neutrophil system and a free cell system, to the following degree: (1) IC50 = 0.265 ± 0.036 μmol L-1; (2) IC50 = 0.250 ± 0.081 μmol L-1; and (3) IC50 = 0.250 ± 0.012 μmol L-1. These values were similar to those for 5-fluorotryptamine (IC50 = 0.192 ± 0.012 μmol L-1), a compound considered to be a potent MPO inhibitor. These aminochalcones were not toxic to neutrophils at concentrations below 100 μmol L- 1, as determined by the trypan blue exclusion assay. Compounds 1–3 presented a high oxidation potential (Epa1 ≈ 0.80 V), low scavenger capacity against DPPH• and HOCl, and low inhibition of respiratory burst. These data indicated that aminochalcones are potent inhibitors of MPO chlorinating activity, a new property for chalcone derivatives, given that they are neither antioxidant agents nor inhibitors of respiratory burst. In conclusion, the selected aminochalcones have potential as pharmacological agents for inflammatory diseases.
Export Options
About this article
Cite this article as:
Zeraik M.L., Ximenes V.F., Regasini L.O., Dutra L.A., Silva D.H.S., Fonseca L.M., Coelho D., Machado S.A.S. and Bolzani V.S., 4’-Aminochalcones As Novel Inhibitors of the Chlorinating Activity of Myeloperoxidase, Current Medicinal Chemistry 2012; 19 (31) . https://dx.doi.org/10.2174/092986712803833344
DOI https://dx.doi.org/10.2174/092986712803833344 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeting MET Receptor in Rhabdomyosarcoma: Rationale and Progress
Current Drug Targets Pharmacophore Modeling for Antitargets
Current Topics in Medicinal Chemistry Resveratrol and Cardiovascular Disease
Current Nutrition & Food Science Effects of Altered Plasminogen Activator Inhibitor-1 Expression on Cardiovascular Disease
Current Drug Targets Renal & Ocular Targets for Therapy in Wegeners Granulomatosis
Inflammation & Allergy - Drug Targets (Discontinued) Evolving Drug Delivery Strategies to Overcome the Blood Brain Barrier
Current Pharmaceutical Design Current Therapeutic Drugs Against Cerebral Vasospasm after Subarachnoid Hemorrhage: A Comprehensive Review of Basic and Clinical Studies
Current Drug Delivery Are Patient Self-Report Questionnaires as "Scientific" as Biomarkers in "Treat-totarget" and Prognosis in Rheumatoid Arthritis?
Current Pharmaceutical Design Therapeutic Potential of Non-Coding RNAs and TLR Signalling Pathways in Rheumatoid Arthritis
Current Pharmaceutical Biotechnology Review of Recent Clinical Developments and Patents for the Treatment of Autoimmune and Inflammatory Diseases by Mesenchymal Stromal Cells
Recent Patents on Regenerative Medicine Anesthetic Cardioprotection: The Role of Adenosine
Current Pharmaceutical Design Thalidomide Metabolism and Hydrolysis: Mechanisms and Implications
Current Drug Metabolism Update on Pharmacologic Retinal Vascular Toxicity
Current Pharmaceutical Design Small-Molecule Chemokine Receptor Antagonists: Potential Targets for Inflammatory and Allergic Disorders
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Update on Clinical, Pathophysiological and Therapeutic Aspects in ANCAAssociated Vasculitides
Current Drug Discovery Technologies Chronic Urticaria: An Overview of Treatment and Recent Patents
Recent Patents on Inflammation & Allergy Drug Discovery Targeting Microenvironment of Melanoma and Head and Neck Cancers in Photodynamic Therapy
Current Medicinal Chemistry Recent Advances in Characterizing Natural Products that Regulate Autophagy
Anti-Cancer Agents in Medicinal Chemistry Cardiovascular Involvement in Pediatric Systemic Autoimmune Diseases: The Emerging Role of Noninvasive Cardiovascular Imaging
Inflammation & Allergy - Drug Targets (Discontinued) Editorial: Cocaine and Cerebral Small Vessel: Is it a Negative Factor for Intravenous Thrombolysis?
Current Vascular Pharmacology